Fredun Pharmaceuticals Soars to All-Time High, Signaling Unmatched Market Strength

Fredun Pharmaceuticals has achieved a significant milestone by reaching an all-time high of Rs. 1971.25 on November 18, 2025. This remarkable performance underscores the company's strong position within the Pharmaceuticals & Biotechnology sector, particularly as it has outperformed its sector by 4.86% today.
The stock has shown impressive momentum, gaining 15.39% over the past three days and opening with a notable 4.93% increase today. Fredun Pharmaceuticals has consistently traded above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating robust short- and long-term performance.

In terms of financial health, the company has reported a remarkable 127.87% growth in net profit, alongside a 39.73% annual increase in net sales. With a return on capital employed (ROCE) of 20.2 and a favorable enterprise value to capital employed ratio of 3.3, Fredun Pharmaceuticals is positioned attractively compared to its peers.

Over the past year, the stock has generated a return of 182.17%, significantly outpacing the broader market. This achievement reflects the company's solid operational performance and consistent positive results over the last six quarters.